ArticleThe Lancet regional health. Europe2024

Axillary clearance and chemotherapy rates in ER+HER2- breast cancer: secondary analysis of the SENOMAC trial.

Tove Filtenborg Tvedskov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.